Special Issue

Cytomegalovirus Management in Solid Organ Transplant Recipients

Submission Deadline: September 15, 2025 (Open) Submit Now

Guest Editor

Priyamvada Singh, MD, FASN

Assistant Professor of Medicine, Department of Medicine [section –transplant nephrology], Ohio State University, The Ohio State University College of Medicine, 395 West 12th Avenue, First floor. Columbus, OH 43210, USA

Website | E-Mail

Research Interests: Long-term survival of solid organ transplant; Post-transplant diabetes; Inequity in transplant and marginal kidneys utilization; Cancer occurrences in transplanted organs

About This Topic

Cytomegalovirus (CMV) is a common opportunistic infection affecting the outcome of solid organ transplantation [SOT]. The highest risk groups are the CMV-seronegative SOT recipients without preexisting CMV-specific immunity who receive a CMV-seropositive donor (D+/R-). Antiviral prophylaxis and preemptive therapy are the cornerstone of CMV prevention. Meanwhile, the reduction of immunosuppression and utilization of antiviral agents are the mainstays of treatment for CMV infection. Due to high cost, side effects [like acute kidney injury and bone marrow suppression], newer treatment options, future vaccine development, and strategies for managing drug-resistant CMV infection require future attention. CMV-specific cell-mediated immune assays are increasingly used to stratify the risk of CMV infection after solid organ transplantation. Still, their role in optimizing CMV prevention and treatment efforts has yet to be demonstrated.

The special issue will provide a forum for presenting evidence-based recommendations for screening, diagnosis, prevention, and treating CMV in solid organ transplant recipients.

Manuscript Submission Information

Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (transplantation@lidsen.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.

Welcome your submission!

Publication

Open Access Review Maribavir for Management of Cytomegalovirus in Lung Transplant Recipients: A Case Series and Literature Review by Jade M Kozuch  , Kamyar Afshar  and Ashley Feist Received: 15 November 2024;  Published: 20 February 2025;  doi: 10.21926/obm.transplant.2501235 Abstract Lung transplant recipients represent a high-risk group for cytomegalovirus (CMV) infection and disease, even among solid organ transplant (SOT) recipients, due to multiple factors. Additionally, CMV has significant consequences in this group including pneumonitis, acute rejection, and chronic lung allograft dysfunction. For the past two plus [...]